PolTREG S.A.

Clinical trials sponsored by PolTREG S.A., explained in plain language.

PolTREG S.A. PTG WSE

Polish biotech developing T-regulatory cell therapies for autoimmune diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1

Could a cell cocktail stop type 1 diabetes before it starts?

Disease control Recruiting now

This study tests whether a combination of special immune cells (Tregs) and a drug (rituximab) can delay or prevent type 1 diabetes in children aged 6–16 who are at high risk but still produce insulin normally. About 150 participants will be randomly assigned to one of four groups…

Phase 2 • Sponsor: PolTREG S.A. • Aim: Disease control

Last updated Jul 19, 2026 00:00 UTC

PolTREG S.A.

Could a cell cocktail stop type 1 diabetes before it starts?